Johnson & Johnson reported Phase 3 results showing Tecvayli reduced the risk of disease progression or death by a substantial margin in patients with early relapsed multiple myeloma. The MajesTEC‑9 trial enrolled patients after frontline therapy and compared Tecvayli to standard regimens; company data show a robust improvement in progression‑free survival and a secondary benefit on overall survival. Regulators have signaled accelerated attention to Tecvayli as J&J moves to broaden the antibody’s use earlier in the disease course, and the company plans regulatory discussions and medical presentations. The readout supports J&J’s strategy to build a dominant myeloma franchise around dual‑targeting antibodies and complementary assets.